LiveWorld Reports First Quarter 2025 Financial Results
LiveWorld (OTC: LVWD) reported its Q1 2025 financial results with total revenues remaining flat at $2.6 million compared to Q1 2024. The company's healthcare segment contributed $2.3 million in revenue. The net loss from operations improved by 45% to $276,000 compared to $498,000 in Q1 2024.
The company's cash position decreased by $1.6 million to $5.0 million, primarily due to timing issues with contract renewals. Accounts receivable significantly increased from $682,000 to $2.3 million. LiveWorld launched its first dedicated AI product, the AI Pharma Brand Reputation Index, in Q1 and plans to release more AI products in beta later this year as part of its increased investment in artificial intelligence initiatives.
LiveWorld (OTC: LVWD) ha comunicato i risultati finanziari del primo trimestre 2025 con ricavi totali stabili a 2,6 milioni di dollari rispetto al primo trimestre 2024. Il segmento sanitario dell'azienda ha contribuito con 2,3 milioni di dollari di ricavi. La perdita netta operativa è migliorata del 45%, attestandosi a 276.000 dollari rispetto ai 498.000 dollari del primo trimestre 2024.
La liquidità dell'azienda è diminuita di 1,6 milioni di dollari, scendendo a 5,0 milioni di dollari, principalmente a causa di tempistiche legate al rinnovo dei contratti. I crediti verso clienti sono aumentati significativamente, passando da 682.000 a 2,3 milioni di dollari. Nel primo trimestre, LiveWorld ha lanciato il suo primo prodotto dedicato all'intelligenza artificiale, l'AI Pharma Brand Reputation Index, e prevede di rilasciare ulteriori prodotti AI in versione beta entro la fine dell'anno, nell'ambito del suo maggiore investimento nelle iniziative di intelligenza artificiale.
LiveWorld (OTC: LVWD) reportó sus resultados financieros del primer trimestre de 2025 con ingresos totales que se mantuvieron estables en 2,6 millones de dólares en comparación con el primer trimestre de 2024. El segmento de salud de la compañía aportó 2,3 millones de dólares en ingresos. La pérdida neta operativa mejoró un 45%, situándose en 276.000 dólares frente a los 498.000 dólares del primer trimestre de 2024.
La posición de efectivo de la empresa disminuyó en 1,6 millones de dólares, quedando en 5,0 millones, principalmente debido a cuestiones de tiempo relacionadas con la renovación de contratos. Las cuentas por cobrar aumentaron significativamente de 682.000 a 2,3 millones de dólares. En el primer trimestre, LiveWorld lanzó su primer producto dedicado a la inteligencia artificial, el AI Pharma Brand Reputation Index, y planea lanzar más productos de IA en versión beta a lo largo del año como parte de su mayor inversión en iniciativas de inteligencia artificial.
LiveWorld(OTC: LVWD)는 2025년 1분기 재무 실적을 발표하며 총 매출이 2024년 1분기와 동일한 260만 달러를 기록했다고 밝혔습니다. 회사의 헬스케어 부문은 230만 달러의 매출을 기여했습니다. 영업 손실은 2024년 1분기의 498,000달러에서 45% 개선된 276,000달러로 감소했습니다.
현금 보유액은 계약 갱신 일정 문제로 인해 160만 달러 감소하여 500만 달러가 되었습니다. 매출채권은 682,000달러에서 230만 달러로 크게 증가했습니다. LiveWorld는 1분기에 첫 번째 AI 전용 제품인 AI Pharma Brand Reputation Index를 출시했으며, 올해 후반에 더 많은 AI 제품을 베타 버전으로 출시할 계획입니다. 이는 인공지능 투자 확대의 일환입니다.
LiveWorld (OTC : LVWD) a publié ses résultats financiers du premier trimestre 2025 avec des revenus totaux stables à 2,6 millions de dollars par rapport au premier trimestre 2024. Le segment santé de la société a contribué pour 2,3 millions de dollars de revenus. La perte nette d'exploitation s'est améliorée de 45 % pour s'établir à 276 000 dollars contre 498 000 dollars au premier trimestre 2024.
La trésorerie de l'entreprise a diminué de 1,6 million de dollars pour atteindre 5,0 millions de dollars, principalement en raison de délais liés aux renouvellements de contrats. Les comptes clients ont fortement augmenté, passant de 682 000 à 2,3 millions de dollars. Au premier trimestre, LiveWorld a lancé son premier produit dédié à l'intelligence artificielle, l'AI Pharma Brand Reputation Index, et prévoit de lancer d'autres produits d'IA en version bêta plus tard cette année dans le cadre de son investissement accru dans les initiatives d'intelligence artificielle.
LiveWorld (OTC: LVWD) meldete seine Finanzergebnisse für das erste Quartal 2025 mit stabilen Gesamterlösen von 2,6 Millionen US-Dollar im Vergleich zum ersten Quartal 2024. Der Gesundheitsbereich des Unternehmens trug 2,3 Millionen US-Dollar zum Umsatz bei. Der operative Nettoverlust verbesserte sich um 45 % auf 276.000 US-Dollar gegenüber 498.000 US-Dollar im ersten Quartal 2024.
Die Barbestände des Unternehmens sanken um 1,6 Millionen US-Dollar auf 5,0 Millionen US-Dollar, hauptsächlich aufgrund von zeitlichen Verzögerungen bei Vertragsverlängerungen. Die Forderungen aus Lieferungen und Leistungen stiegen deutlich von 682.000 auf 2,3 Millionen US-Dollar. Im ersten Quartal brachte LiveWorld sein erstes dediziertes KI-Produkt, den AI Pharma Brand Reputation Index, auf den Markt und plant, im Laufe des Jahres weitere KI-Produkte in der Beta-Version zu veröffentlichen, als Teil seiner verstärkten Investitionen in KI-Initiativen.
- Net loss from operations improved by 45% year-over-year to $276,000
- Accounts receivable grew significantly from $682,000 to $2.3 million, indicating strong future cash collections
- Successfully launched first AI product (AI Pharma Brand Reputation Index)
- Maintains strong cash position of $5.0 million
- Flat revenue growth at $2.6 million year-over-year
- Cash burn of $1.5 million in Q1 2025
- Management warns of potential incremental losses due to AI investments
- Net cash decreased by $1.6 million from December 2024
LiveWorld looks to increase its AI investment
CAMPBELL, Calif. and NEW YORK , May 08, 2025 (GLOBE NEWSWIRE) -- LiveWorld, Inc. (OTC Markets: LVWD), today announced financial results for first quarter 2025.
Three Months 2025 Financial and Business Highlights
- Total three months revenues of
$2.6 million - Healthcare revenues of
$2.3 million in Q1 2025 - Net loss from operations of
$276,000 a reduction of45% when compared to 2024 - Net Cash decreased by
$1.6 million to$5.0 million from December 31, 2024
Management Commentary
“In the first quarter of the 2025 our total revenues were relatively flat when comparing 2024 to 2025, as both were approximately
“For the three months ended March 31, 2025, we saw a cash burn of approximately
“Our focus continues to bring value to our clients through the integration of a human touch with advanced technology,” said Peter Friedman, LiveWorld Chairman & CEO. “To support this vision during 2024 and continuing in 2025 we are expanding our investment in AI. Our first dedicated AI product, the AI Pharma Brand Reputation Index, was launched in Q1. We expect to be in beta for our next generation of AI products later this year.”
Financial Review for the Three Months Ended March 31, 2025
Total revenues were flat when comparing the first quarter of 2025 to 2024. Revenues were approximately
The company reported a net loss for the three months of approximately
The company finished the quarter with approximately
Detailed financial information may be downloaded at www.liveworld.com/ir (LiveWorld’s Investor Relations page) or at https://www.otcmarkets.com/stock/LVWD/overview.
About LiveWorld
LiveWorld is a social-first digital agency and software company that unlocks the full potential of social media to transform customer relationships through integrated compliance, engagement, and insight solutions. We provide brand marketers bold creative rooted in strategy that captivates and resonates, social moderation and engagement that activates interactions, software that enriches customer experiences, and compliance that enables and accelerates digital programs.
With over 29 years of making connections, we leverage our social media DNA to deliver emotion-driven behavior change through digital campaigns with a human touch. LiveWorld clients include the number one brands in pharmaceuticals, healthcare, and financial-travel services. LiveWorld is headquartered in Campbell, California, with an additional office in New York City. Learn more at www.liveworld.com and @LiveWorld.
“Safe Harbor" Statement Under The Private Securities Litigation Reform Act
This press release may contain forward-looking information concerning LiveWorld plans, objectives, future expectations, forecasts and prospects. These statements may include those regarding LiveWorld’s current or future financial performance including but not limited to lists of clients, revenue and profit, use of cash, investments, relationships and the actual or potential impact of stock option expense, and the results of its product development efforts. Actual results may differ materially from those expressed in the forward- looking statements made as a result of, among other things, final accounting adjustments and results, LiveWorld’s ability to attract new clients and preserve or expand its relationship with existing clients, LiveWorld’s ability to retain and attract high quality employees, including its management staff, the ability to deliver new innovative products in a timely manner, changing accounting treatments, and other risks applicable to the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to update these forward-looking statements to reflect subsequent events or circumstances.
LiveWorld Contacts
IR Contact:
David Houston
LiveWorld
dhouston@liveworld.com
(408) 615-8496
PR Contact:
Matthew Hammer
LiveWorld
mhammer@liveworld.com
(737) 212-9739
LIVEWORLD, INC. | |||||||
UNAUDITED CONDENSED BALANCE SHEETS | |||||||
(In thousands, except share data) | |||||||
March 31, | December 31, | ||||||
2025 | 2024 | ||||||
ASSETS | |||||||
Current assets | |||||||
Cash and cash equivalent | $ | 5,045 | $ | 6,603 | |||
Accounts receivable, net | 2,342 | 682 | |||||
Prepaid expenses | 461 | 290 | |||||
Total current assets | 7,848 | 7,575 | |||||
Property and equipment, net | 31 | 33 | |||||
Other assets | 27 | 27 | |||||
Total assets | $ | 7,906 | $ | 7,635 | |||
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
Current liabilities | |||||||
Accounts payable | $ | 213 | $ | 182 | |||
Accrued employee expenses | 581 | 1,068 | |||||
Other accrued liabilities | 337 | 413 | |||||
Deferred revenue | 1,860 | 860 | |||||
Total current liabilities | 2,991 | 2,523 | |||||
Total liabilities | 2,991 | 2,523 | |||||
Stockholders' equity | |||||||
Common stock: | 34 | 34 | |||||
Additional paid-in capital | 144,530 | 144,451 | |||||
Accumulated deficit | (139,649 | ) | (139,373 | ) | |||
Total stockholders' equity | 4,915 | 5,112 | |||||
Total liabilities and stockholders' equity | $ | 7,906 | $ | 7,635 |
LIVEWORLD, INC. | |||||||
CONDENSED STATEMENT OF OPERATIONS | |||||||
(In thousands, except per share data) | |||||||
Three Months Ended March 31, | |||||||
2025 | 2024 | ||||||
Total revenues | $ | 2,575 | $ | 2,572 | |||
Cost of revenues | 1,514 | 1,577 | |||||
Gross Margin | 1,061 | 995 | |||||
Operating Expense | |||||||
Product development | 275 | 272 | |||||
Sales and marketing | 440 | 510 | |||||
General and administrative | 638 | 711 | |||||
Total operating expense | 1,353 | 1,493 | |||||
Income from operations | (292 | ) | (498 | ) | |||
Income before tax | (292 | ) | (498 | ) | |||
Other Income | 17 | 1 | |||||
Provision for income taxes | (1 | ) | 1 | ||||
Net income from operations | (276 | ) | (498 | ) | |||
Earnings per share analysis from operations: | |||||||
Basic income per share | $ | (0.01 | ) | $ | (0.01 | ) | |
Shares used in computing basic loss per share | 45,633,442 | 45,633,442 | |||||
Diluted net income (loss) per share | $ | (0.01 | ) | $ | (0.01 | ) | |
Shares used in computing diluted income (loss) per share | 45,633,442 | 45,633,442 | |||||
Departmental allocation of stock-based compensation: | |||||||
Cost of revenues | $ | 20 | $ | 18 | |||
Product development | 5 | 5 | |||||
Sales and marketing | 8 | 8 | |||||
General and administrative | 46 | 45 | |||||
Total stock-based compensation | $ | 79 | $ | 76 |
LIVEWORLD, INC. | |||||||
CONDENSED STATEMENTS OF CASH FLOWS | |||||||
(In thousands) | |||||||
Three Months Ended March 31, | |||||||
2025 | 2024 | ||||||
Cash flows from operating activities: | |||||||
Net income (loss) | $ | (276 | ) | $ | (498 | ) | |
Adjustments to reconcile net income (loss) provided by (used in) operating activities: | |||||||
Depreciation of long-lived assets | 6 | 6 | |||||
Stock-based compensation | 79 | 76 | |||||
Changes in operating assets and liabilities: | |||||||
Accounts receivable | (1,660 | ) | (562 | ) | |||
Other assets | (171 | ) | (124 | ) | |||
Accounts payable | 31 | (2 | ) | ||||
Accrued liabilities | (563 | ) | (214 | ) | |||
Deferred revenue | 1,000 | 1,004 | |||||
Net cash provided by (used in) operating activities | (1,554 | ) | (314 | ) | |||
Cash flows from investing activities: | |||||||
Purchase of property and equipment | (4 | ) | (5 | ) | |||
Net cash provided by (used in) investing activities | (4 | ) | (5 | ) | |||
Cash flows from financing activities: | |||||||
Proceeds from exercise of stock options | ---- | ---- | |||||
Net cash provided by (used for) financing activities | ---- | ---- | |||||
Change in cash and cash equivalent | (1,558 | ) | (319 | ) | |||
Cash and cash equivalents, beginning of period | 6,603 | 4,635 | |||||
Cash and cash equivalents, end of period | $ | 5,045 | $ | 4,316 | |||
Supplemental disclosure of non-cash financing and investing activities: | |||||||
Income tax paid | $ | 1 | $ | 1 |
